Raul Shah braves the snow and cold to join Morning Movers from the NYSE floor. He discusses Hims & Hers (HIMS) ahead of earnings. The company's faced multiple headwinds including legal issues from Novo Nordisk (NVO) and its sale of a semaglutide weight-loss product. Raul says the earnings call "will be crucial" for investors to get some clarity from the company's leaders and more insights on Hims & Hers next steps. Raul points to other markets like hormonal treatment as a potential growth area for HIMS.
Morning Movers
23 Feb 2026
SHARE